See more : Visual Photonics Epitaxy Co., Ltd. (2455.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Perrigo Company plc (PRGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perrigo Company plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Axon Partners Group, S.A. (APG.MC) Income Statement Analysis – Financial Results
- Pickles Corporation (2925.T) Income Statement Analysis – Financial Results
- United Energy Corp. (UNRG) Income Statement Analysis – Financial Results
- Unigold Inc. (UGDIF) Income Statement Analysis – Financial Results
- International Baler Corporation (IBAL) Income Statement Analysis – Financial Results
Perrigo Company plc (PRGO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.perrigo.com
About Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66B | 4.45B | 4.14B | 5.06B | 4.84B | 4.73B | 4.95B | 5.28B | 4.60B | 4.06B | 3.54B | 3.17B | 2.76B | 2.27B | 2.01B | 1.82B | 1.45B | 1.37B | 1.02B | 898.20M | 825.99M | 826.32M | 753.49M | 738.56M | 877.60M | 902.60M | 844.60M | 778.10M | 717.10M | 669.30M | 570.80M | 409.80M |
| Cost of Revenue | 2.98B | 3.00B | 2.72B | 3.25B | 3.06B | 2.90B | 2.97B | 3.23B | 2.89B | 2.61B | 2.26B | 2.08B | 1.81B | 1.52B | 1.41B | 1.27B | 1.05B | 969.08M | 763.71M | 630.24M | 596.08M | 614.42M | 568.99M | 561.07M | 670.80M | 641.40M | 587.10M | 547.60M | 496.60M | 456.10M | 390.10M | 278.60M |
| Gross Profit | 1.68B | 1.46B | 1.42B | 1.82B | 1.77B | 1.83B | 1.98B | 2.05B | 1.71B | 1.45B | 1.28B | 1.10B | 944.87M | 746.02M | 596.00M | 550.96M | 401.63M | 397.74M | 260.39M | 267.96M | 229.91M | 211.90M | 184.49M | 177.49M | 206.80M | 261.20M | 257.50M | 230.50M | 220.50M | 213.20M | 180.70M | 131.20M |
| Gross Profit Ratio | 36.09% | 32.69% | 34.22% | 35.85% | 36.66% | 38.71% | 40.02% | 38.86% | 37.19% | 35.65% | 36.16% | 34.53% | 34.30% | 32.88% | 29.70% | 30.24% | 27.75% | 29.10% | 25.43% | 29.83% | 27.83% | 25.64% | 24.49% | 24.03% | 23.56% | 28.94% | 30.49% | 29.62% | 30.75% | 31.85% | 31.66% | 32.02% |
| Research & Development | 122.50M | 123.10M | 122.00M | 177.70M | 187.40M | 218.60M | 167.70M | 184.00M | 187.80M | 152.50M | 115.20M | 105.77M | 89.25M | 82.51M | 77.92M | 72.19M | 66.48M | 52.29M | 38.42M | 27.72M | 23.32M | 19.89M | 17.63M | 16.31M | 14.90M | 15.90M | 13.70M | 0.00 | 0.00 | 6.20M | 0.00 | 0.00 |
| General & Administrative | 522.30M | 512.30M | 482.00M | 496.00M | 503.00M | 435.90M | 461.10M | 452.20M | 385.20M | 411.30M | 426.30M | 240.20M | 224.40M | 270.70M | 231.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 752.30M | 697.80M | 629.40M | 679.50M | 663.10M | 689.90M | 685.40M | 753.30M | 386.60M | 263.90M | 47.50M | 233.60M | 187.40M | 28.39M | 24.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.27B | 1.21B | 1.11B | 1.18B | 1.17B | 1.13B | 1.15B | 1.21B | 771.80M | 675.20M | 473.80M | 411.84M | 364.38M | 299.09M | 255.84M | 276.19M | 227.46M | 225.27M | 159.26M | 137.35M | 124.55M | 114.24M | 107.97M | 107.60M | 152.80M | 277.70M | 143.10M | 135.10M | 121.30M | 97.90M | 91.80M | 65.30M |
| Other Expenses | 131.40M | 800.00K | -417.60M | -3.70M | 4.20M | -6.10M | 10.10M | -22.70M | -343.20M | -12.40M | -900.00K | 0.00 | -42.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.13M | -16.37M | -18.60M | 22.25M | 21.10M | 29.40M | 28.60M | 27.20M | 23.70M | 18.90M | 15.40M | 12.00M |
| Operating Expenses | 1.53B | 1.33B | 815.80M | 1.35B | 1.36B | 1.35B | 1.27B | 1.39B | 959.60M | 827.70M | 589.00M | 517.62M | 411.32M | 381.60M | 333.76M | 348.38M | 293.94M | 277.56M | 197.68M | 165.07M | 144.73M | 117.77M | 107.01M | 146.16M | 188.80M | 323.00M | 185.40M | 162.30M | 145.00M | 123.00M | 107.20M | 77.30M |
| Cost & Expenses | 4.50B | 4.33B | 3.54B | 4.60B | 4.42B | 4.25B | 4.24B | 4.62B | 3.85B | 3.44B | 2.85B | 2.60B | 2.22B | 1.90B | 1.74B | 1.62B | 1.34B | 1.25B | 961.39M | 795.31M | 740.81M | 732.19M | 676.00M | 707.23M | 859.60M | 964.40M | 772.50M | 709.90M | 641.60M | 579.10M | 497.30M | 355.90M |
| Interest Income | 0.00 | 140.70M | 119.70M | 130.60M | 125.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 173.80M | 156.00M | 125.00M | 125.00M | 121.70M | 129.00M | 173.40M | 218.80M | 155.70M | 175.80M | 103.50M | 0.00 | 42.31M | 28.78M | 27.15M | 17.04M | 16.02M | 5.40M | 220.00K | 220.00K | 0.00 | 0.00 | 0.00 | 840.00K | 14.00M | 4.20M | 1.20M | 5.70M | 5.40M | 3.30M | 3.40M | 8.80M |
| Depreciation & Amortization | 359.50M | 338.60M | 312.20M | 384.80M | 396.50M | 423.60M | 444.80M | 457.00M | 548.80M | 358.90M | 160.20M | 135.32M | 102.94M | 76.13M | 70.14M | 69.23M | 58.03M | 56.60M | 34.81M | 28.45M | 26.13M | 25.61M | 23.02M | 22.25M | 21.10M | 29.40M | 28.60M | 27.20M | 23.70M | 18.90M | 15.40M | 12.00M |
| EBITDA | 525.00M | 507.20M | 915.60M | 661.90M | 612.90M | 906.00M | 1.14B | -4.18B | 754.30M | 1.21B | 939.40M | 858.90M | 713.30M | 594.10M | 411.17M | 325.31M | 288.54M | 157.13M | 177.75M | -293.90M | 131.35M | 111.30M | 113.68M | 49.42M | 59.21M | 45.17M | -32.40M | 95.40M | 99.20M | 109.10M | 88.90M | 65.90M |
| EBITDA Ratio | 11.28% | 11.49% | 21.41% | 26.01% | 20.69% | 20.35% | 28.71% | 121.02% | 16.69% | 29.81% | 24.52% | 22.48% | 21.57% | 19.42% | 16.56% | 15.19% | 11.63% | 12.86% | 47.92% | 14.62% | 13.10% | 13.37% | 15.83% | 6.69% | 4.46% | -3.59% | 11.92% | 12.26% | 13.83% | 16.30% | 15.57% | 16.08% |
| Operating Income | 151.90M | 172.80M | 573.70M | 932.40M | 604.50M | 236.50M | 598.20M | -2.00B | 747.60M | 567.00M | 679.10M | 569.23M | 490.21M | 335.90M | 247.31M | 197.48M | 98.55M | 111.33M | -330.47M | 102.90M | 85.18M | 87.00M | 40.11M | 31.33M | 18.00M | -61.80M | 72.10M | 68.20M | 75.50M | 90.20M | 73.50M | 53.90M |
| Operating Income Ratio | 3.26% | 3.88% | 13.86% | 18.41% | 12.50% | 5.00% | 12.09% | -37.87% | 16.24% | 13.96% | 19.18% | 17.94% | 17.79% | 14.80% | 12.32% | 10.84% | 6.81% | 8.15% | -32.27% | 11.46% | 10.31% | 10.53% | 5.32% | 4.24% | 2.05% | -6.85% | 8.54% | 8.76% | 10.53% | 13.48% | 12.88% | 13.15% |
| Total Other Income/Expenses | -160.20M | -218.00M | -151.70M | -259.30M | -33.80M | 54.10M | -318.10M | -2.85B | -499.60M | -412.20M | -267.80M | -71.40M | -57.20M | -39.60M | -27.25M | -43.53M | -16.91M | -5.40M | -5.40M | -433.59M | -1.66M | 1.08M | 1.36M | 3.75M | -4.99M | -14.02M | -4.20M | -1.20M | -5.70M | -5.40M | -3.30M | -3.40M |
| Income Before Tax | -8.30M | -139.10M | 258.70M | -149.40M | 171.00M | 290.60M | 280.10M | -4.85B | 248.00M | 272.60M | 607.70M | 511.99M | 450.55M | 308.19M | 203.78M | 180.44M | 89.05M | 105.94M | -330.69M | 105.98M | 86.26M | 88.35M | 43.86M | 30.49M | 4.00M | -66.00M | 70.90M | 62.50M | 70.10M | 86.90M | 70.10M | 45.10M |
| Income Before Tax Ratio | -0.18% | -3.12% | 6.25% | -2.95% | 3.53% | 6.14% | 5.66% | -91.81% | 5.39% | 6.71% | 17.17% | 16.13% | 16.35% | 13.58% | 10.15% | 9.90% | 6.15% | 7.75% | -32.29% | 11.80% | 10.44% | 10.69% | 5.82% | 4.13% | 0.46% | -7.31% | 8.39% | 8.03% | 9.78% | 12.98% | 12.28% | 11.01% |
| Income Tax Expense | -3.90M | -8.20M | 389.60M | 13.20M | 24.90M | 159.60M | 160.50M | -835.50M | 120.10M | 67.30M | 165.80M | 119.02M | 110.00M | 84.09M | 62.68M | 44.67M | 15.26M | 34.54M | 22.29M | 25.42M | 32.21M | 38.16M | 16.20M | 11.19M | 2.50M | -14.40M | 25.90M | 22.70M | 25.70M | 32.10M | 25.50M | 16.50M |
| Net Income | -12.70M | -130.90M | -130.90M | -162.60M | 146.10M | 131.00M | 119.60M | -4.01B | 127.90M | 205.30M | 441.90M | 401.61M | 339.20M | 222.55M | 144.05M | 135.77M | 73.80M | 71.40M | -352.98M | 80.57M | 54.05M | 50.20M | 27.66M | 19.30M | 1.50M | -51.60M | 45.00M | 39.80M | 44.40M | 54.80M | 44.60M | 28.60M |
| Net Income Ratio | -0.27% | -2.94% | -3.16% | -3.21% | 3.02% | 2.77% | 2.42% | -75.99% | 2.78% | 5.06% | 12.48% | 12.66% | 12.31% | 9.81% | 7.18% | 7.45% | 5.10% | 5.22% | -34.47% | 8.97% | 6.54% | 6.07% | 3.67% | 2.61% | 0.17% | -5.72% | 5.33% | 5.12% | 6.19% | 8.19% | 7.81% | 6.98% |
| EPS | -0.09 | -0.97 | -0.98 | -1.19 | 1.07 | 0.95 | 0.84 | -28.01 | 0.92 | 1.78 | 4.71 | 4.31 | 3.67 | 2.43 | 1.56 | 1.46 | 0.80 | 0.77 | -4.57 | 1.15 | 0.77 | 0.69 | 0.38 | 0.26 | 0.02 | -0.69 | 0.58 | 0.52 | 0.58 | 0.71 | 0.58 | 0.41 |
| EPS Diluted | -0.09 | -0.97 | -0.98 | -1.19 | 1.07 | 0.95 | 0.84 | -28.00 | 0.91 | 1.78 | 4.68 | 4.27 | 3.63 | 2.40 | 1.54 | 1.43 | 0.79 | 0.76 | -4.57 | 1.11 | 0.76 | 0.67 | 0.37 | 0.26 | 0.02 | -0.69 | 0.58 | 0.51 | 0.58 | 0.71 | 0.58 | 0.41 |
| Weighted Avg Shares Out | 135.30M | 134.50M | 133.60M | 136.10M | 136.00M | 137.80M | 142.30M | 143.26M | 139.30M | 115.10M | 93.90M | 93.20M | 92.30M | 91.40M | 92.18M | 93.12M | 92.23M | 92.88M | 77.31M | 70.21M | 69.75M | 73.16M | 73.65M | 73.37M | 75.00M | 74.78M | 77.43M | 77.20M | 76.55M | 77.18M | 76.90M | 69.76M |
| Weighted Avg Shares Out (Dil) | 135.30M | 134.50M | 133.60M | 136.10M | 136.50M | 138.30M | 142.60M | 143.30M | 139.80M | 115.60M | 94.50M | 94.10M | 93.50M | 92.85M | 93.63M | 95.21M | 93.81M | 94.11M | 77.31M | 72.29M | 71.16M | 74.61M | 74.09M | 73.54M | 75.00M | 74.78M | 77.43M | 77.78M | 76.55M | 77.18M | 76.90M | 69.76M |
Perrigo Completes Divestment of HRA Pharma Rare Diseases Business
DUBLIN , July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that it has completed the previously announced divestment of the HRA Pharma Rare Diseases business...
Notice of Proposed Settlement and Plan of Allocation Involving Purchasers of Perrigo Common Stock from April 21, 2015 through May 2, 2017 and Owners of Perrigo Common Stock as of November 12, 2015
SEATTLE, June 24, 2024 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference
DUBLIN , May 28, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 24th Annual...
Understanding Perrigo (PRGO) Reliance on International Revenue
Explore how Perrigo's (PRGO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo;...
Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business
Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN , May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of...
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Source: https://incomestatements.info
Category: Stock Reports